FIELD: medicine; oncology.
SUBSTANCE: present invention concerns treating Epstein—Barr virus-associated lymphoproliferative disease (EBV-LPD) associated with B-cells. That is ensured by introducing a population of allogenic T-cells containing EBV-specific T-cells limited by a human leukocyte antigen (HLA) allele identical to EBV-LPD cells.
EFFECT: invention provides successful treatment of said disease, including in patients resistant to previous combined chemo-, radiation therapy, as well as anti-CD20 monoclonal antibody therapy.
69 cl, 1 ex, 1 tbl
